
Gazyva Approved as First Drug for Primary Membranous Nephropathy
Key Takeaways
- FDA approved obinutuzumab as the first disease-specific option for primary membranous nephropathy, targeting B-cell–driven autoimmunity underlying progressive proteinuric glomerular injury.
- MAJESTY showed superior efficacy versus off-label tacrolimus at week 104, with complete remission 36% vs <6% and overall remission 50% vs ~13%.
Despite Gazyva being the first drug accepted to treat this type of nephropathy, it’s already approved for a host of other conditions.
The FDA has approved obinutuzumab (Gazyva) to induce remission of proteinuria in adults with primary membranous nephropathy at risk of disease progression, making it the first drug approved specifically for the autoimmune kidney disease, according to an FDA release.1
“The FDA approval of Gazyva represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” said Levi Garraway, MD, PhD, chief medical officer and head of global product development with Genentech, according to a separate release.2 “With Gazyva, we are turning decades of specialized antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases.”
As a glycoengineered Type II anti-CD20 monoclonal antibody, obinutuzumab works by directly depleting targeted B cells to suppress antibody-mediated autoimmune destruction within kidney tissue. Although this milestone represents the first FDA-approved treatment specifically for primary membranous nephropathy, the drug already possesses established therapeutic indications across hematologic malignancies, active lupus nephritis, and pediatric nephrotic syndrome.1-3
READ MORE:
This expanding footprint across autoimmune conditions underscores a broader shift toward targeted biological therapies in modern nephrology practice.2
Clinical Trial Evidence and Disease Impact
Primary membranous nephropathy is a rare autoimmune disease caused by immune system attacks on the glomeruli, leading to severe proteinuria, swelling, and progressive renal damage. Without effective intervention, up to 30% of patients progress to kidney failure within 10 years.1-3
The landmark phase 3 MAJESTY study demonstrated that obinutuzumab achieved a complete remission rate of proteinuria in 36% of adult patients at week 104, compared with less than 6% among those receiving off-label tacrolimus. Furthermore, overall remission reached 50% in the obinutuzumab group compared with nearly 13% in the control group. The treatment was granted Breakthrough Therapy, Orphan Drug, and Priority Review designations by FDA, highlighting its urgent therapeutic need.
Safety evaluations in the MAJESTY study showed comparable rates of grade 3 or higher adverse events between obinutuzumab and tacrolimus, with 22% and 19% reported respectively. The prescribing information includes boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.1-3
Common side effects observed during trials included upper respiratory tract infections and infusion-related reactions. Because these severe safety parameters require ongoing vigilance, health care providers must carefully evaluate candidate patients prior to therapy initiation.1,2
The Pivotal Role of Pharmacists in Nephropathy Care
As advanced biological therapies transform nephrology, clinical and community pharmacists play an indispensable role in optimizing patient outcomes. In chronic kidney disease management, systematic meta-analysis evidence reveals that structured pharmacist interventions significantly reduce systolic blood pressure and improve hemoglobin levels through comprehensive medication management.4
Pharmacists are uniquely positioned to manage complex dosing algorithms, conduct medication reconciliations, and prevent drug-related problems associated with immunosuppressive therapy. Studies demonstrate that dedicated pharmaceutical care enhances medication adherence, increases patient disease awareness, and delivers substantial cost savings by reducing unnecessary hospitalizations.
For patients prescribed obinutuzumab for primary membranous nephropathy, pharmacists will serve as vital guardians of therapeutic safety and treatment compliance. They lead pre-treatment screening protocols for viral reactivations, coordinate premedication regimens to mitigate infusion-related reactions, and educate patients on recognizing infection risks.1,2,4
By integrating ongoing therapeutic monitoring with tailored patient education, pharmacy professionals ensure that novel disease-modifying biologics achieve their full clinical potential across primary care settings and specialized nephrology clinics alike.4
“By achieving significantly higher complete remission rates compared with tacrolimus, Gazyva offers a more effective approach to help achieve durable disease control,” concluded Garraway.2
READ MORE:
REFERENCES
1. FDA approves first drug to treat adults with primary membranous nephropathy. FDA. News Release. November 13, 2026. Accessed November 16, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy
2. Genentech’s Gazyva becomes the first FDA-approved treatment for primary membranous nephropathy. Genentech. News Release. November 13, 2026. Accessed November 16, 2026. https://www.gene.com/media/press-releases/15143/2026-11-15/genentechs-gazyva-becomes-the-first-fda-
3. FDA grants obinutuzumab priority review as primary membranous nephropathy’s potential first therapy. HCPLive. July 15, 2026. Accessed November 16, 2026. https://www.hcplive.com/view/fda-grants-obinutuzumab-priority-review-primary-membranous-nephropathy-s-potential-first-therapy
4. Ardavani A, Curtis F, Hopwood E, et al. Effect of pharmacist interventions in chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2025;40(5):884-907. doi:10.1093/ndt/gfae221
Related to this article








